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Abstract 27 
Aims: Some allogeneic cell therapies requiring a high dose of cells for large indication 28 
groups demand a change in cell expansion technology, from planar units for the early 29 
development phases to microcarriers in single-use bioreactors for the market phase. The aim 30 
was to model the optimal timing for making this change. Materials and Methods: A 31 
development lifecycle cash flow framework was created to examine the implications of 32 
process changes to microcarrier cultures at different stages of a cell therapy’s lifecycle. 33 
Results: The analysis performed under assumptions used in the framework predicted that 34 
making this switch earlier in development is optimal from a total expected out-of-pocket cost 35 
perspective. From a risk-adjusted net present value (rNPV) view, switching at phase 1 is also 36 
economically competitive but a post-approval switch can offer the highest rNPV as the cost 37 
of switching is offset by initial market penetration with planar technologies. Conclusions: 38 
The framework can facilitate early decision-making during process development. 39 
 40 
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Introduction 48 
Approximately 40% of cell therapies in development are allogeneic (i.e. universal rather than 49 
patient-specific) [1, 2, 3]. The worldwide stem cell therapy market is projected to grow at a 50 
compound annual growth rate of 39.5% from 2015 to 2020 and is predicted to reach $330 51 
million by 2020 [4].The growing number of allogeneic cell therapy products in later-stage 52 
clinical trials is heralding a new era for the cell therapy sector. Hurdles firms face in scaling 53 
up manufacturing of these cell therapy products, however, remain a key challenge for the 54 
industry as it expands [5, 6, 7].  55 
For most allogeneic cell therapy products in development or on the market, cell 56 
expansion is carried out using either planar technologies such as T-flasks or multi-layer 57 
stacked vessels (e.g. Cell Factories (Nunc, ThermoFischer Scientific, Waltham, MA) or Cell-58 
STACKs (Corning Incorporated Life Sciences, Tewksbury, MA)). This practice can be 59 
attributed to in-house expertise as well as their ease of scale-up and direct translation from T-60 
flasks or 1-2 layer vessels due to their similar cell growth platform. In contrast, microcarrier 61 
cultures have a greater scalability potential, incorporate automation and control and are hence 62 
more suited to large-scale commercialisation. Recently, the successful culture of stem cells 63 
on microcarriers that were long-established for the culturing of adherent cells in suspension 64 
culture for vaccine production has also been demonstrated [8,9] and opened up the 65 
opportunity to the use of more scalable three-dimensional microcarrier-based single-use 66 
bioreactors.  67 
However, making process changes is complicated by the fact that proving 68 
comparability can be difficult with existing characterisation methods for cell therapies. Thus, 69 
the ability to demonstrate product equivalence following modifications in the manufacturing 70 
process is dependent on developing robust manufacturing processes capable of producing cell 71 
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therapy products with reproducible critical quality attributes [10]. The main challenge is to 72 
set process boundaries such that the product is delivered to high quality, safety and efficacy, 73 
taking into account variation in master cell banks for allogeneic cell therapies. This effort 74 
should be done while maintaining a low cost of goods and a low cost of validation [10]. Even 75 
minimal expansion in cell culture can cause potential alterations in cells that may only be 76 
determined by later testing of the cell’s structural, biological and functional properties [10, 77 
11, 12]. Significant challenges remain, however, in gaining a better understanding of 78 
mechanisms of action, characterising the product’s critical quality attributes and how changes 79 
in manufacturing processes can affect these [10]. 80 
Trade-offs managers face in making manufacturing process decisions in the 81 
development of allogeneic cell therapies are similar to those faced by managers in the 82 
biopharmaceutical industry. In the latter, manufacturing decisions made during the early 83 
stages of research and development have been found to be pivotal decisions with long-lasting 84 
consequences for a project’s commercial feasibility such as market impact and changes in 85 
public policy [13]. On the one hand, making changes to manufacturing processes later on in 86 
the product development pathway results in increased risks of development delays, for 87 
example because firms may be required to run additional clinical trials to demonstrate 88 
product equivalence [14]. On the other hand, finalising manufacturing processes early on in 89 
the development process may be economically unattractive due to high failure rates at this 90 
stage of the process.  91 
Previous cost analyses have shown that microcarrier cultures offer cost of goods 92 
benefits that challenge the established position of planar technologies and, for large lot sizes, 93 
they are the only feasible technology option [15]. From a downstream perspective, single-use 94 
tangential flow filtration has been shown to be more cost-effective for smaller lot sizes and 95 
fluidised bed centrifugation has been shown to be the only feasible option for very large lot 96 
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sizes [16].  However, models that incorporate both cost of goods and drug development costs, 97 
as well as reimbursement profiles and risks, have not been presented in this sector. This paper 98 
extends the cost of goods analyses for whole processes to consider whether the cost of goods 99 
savings with microcarrier-based processes outweigh the cost of drug development. This 100 
analysis was achieved by developing a lifecycle cash flow framework to investigate the cost, 101 
risk, and project valuation implications of upstream process changes to more scalable 102 
expansion technologies at different stages of a cell therapy’s development pathway. A case 103 
study is outlined that focuses on the impact of using standard planar processes throughout all 104 
the clinical phases of development through to market, versus switching to microcarrier-based 105 
single-use bioreactors at different points in the lifecycle.  106 
The lower costs of commercial manufacturing with microcarrier systems were 107 
weighed-up against costs for activities such as process development, process characterisation, 108 
technology transfer and comparability studies, as well as time-delays and risks. To estimate 109 
the impact of process changes, it is also necessary to account for the final product’s revenue 110 
in the future, the cost and time required before market launch, and risks along the product 111 
development pathway [17]. Hence, the process change evaluation framework comprised three 112 
models. The first was a cost of goods model to determine clinical and commercial 113 
manufacturing costs. The second was a cost of the development model that combined clinical 114 
manufacturing cost of goods with process development, technology transfer, and 115 
comparability costs. The third was a development lifecycle cash flow model utilizing the risk-116 
adjusted net present value method to estimate a project’s valuation. This integrated 117 
framework was used to provide a holistic assessment of the financial implications of process 118 
changes at different stages of the development pathway. This type of analysis can smooth the 119 
progress of manufacturing decisions during process development and be used to lower the 120 
risk of process changes during a product’s development cycle. 121 
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Materials and Methods 122 
The process change evaluation framework comprised three key models to determine the cost 123 
of goods, the cost of drug development and project valuation using net present value. The 124 
time required for process changes and the impact of risk were also incorporated. 125 
Cost of goods tool description 126 
A bioprocess economics and optimization model was developed to determine the cost of 127 
goods values for different process flowsheets that spanned cell expansion through to volume 128 
reduction and filling. A decisional-support tool considering whole bioprocessing for 129 
manufacturing a generic allogeneic mesenchymal stromal cell was developed [15, 16].  The 130 
model was designed to address the challenge of identifying the most cost-effective upstream, 131 
downstream and fill-finish technologies and their sizes for cell therapies across a range of 132 
doses, demands, and lots sizes. The model was developed in C# with the .NET framework 133 
(Microsoft1 Visual Studio 2010, Microsoft Corporation, Redmond, WA) linked to 134 
Microsoft Access (Microsoft Corporation, Redmond, WA). The bioprocess economics 135 
model, together with the input database, established process flowsheets under process and 136 
technology-specific constraints, and according to resource consumption and size of 137 
equipment. Once the optimal upstream processing (USP) technology was fixed, the 138 
downstream processing (DSP) cost of goods per dose (COGDSP/dose) was determined for a 139 
particular flowsheet. The overall process COG/dose was determined by the sum of the annual 140 
direct operating costs (i.e. materials, labor and quality control, (QC)) and indirect costs 141 
(facility-dependent fixed capital investment depreciation and maintenance costs) divided by 142 
the annual product output in the number of doses/year. Further details of the cost of goods 143 
model for upstream and downstream cell therapy processes can be found in Simaria et al. [15] 144 
and Hassan et al. [16]. 145 
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Cost of development tool description 146 
A framework for determining the costs of development activities was created and 147 
implemented in Microsoft Excel (Microsoft Corporation, Redmond, WA). Table 1 148 
summarizes assumptions about different activities that occur in the project’s development 149 
pathway and the cost basis of calculations used in this study to estimate the total cost of these 150 
activities. Figure 1 shows the model components used for this analysis. Both process 151 
development and technology transfer activities were assessed on a full-time equivalent (FTE) 152 
basis. For stability studies, the cost per test was considered as the sum of the material and 153 
labor costs for the assay, and the facility-dependent indirect cost per assay, divided by the 154 
total number of assay equipment uses per year. 155 
Process performance qualification (PPQ) batches, manufacturing costs and comparability and 156 
bioequivalence costs were calculated according to manufacturing costs using the decisional 157 
tool.  Estimations of in vitro and in vivo testing for comparability and bioequivalence costs 158 
were also included. Clinical trial costs were estimated according to clinical trial cost per 159 
patient and the number of patients for each trial phase. 160 
Cell therapy project valuation tool description 161 
The cell therapy valuation model was developed in Microsoft Excel (Microsoft 162 
Corporation, Redmond, WA). The tool produces estimates of a project’s cash flows based on 163 
project parameters provided by the user. User inputs included parameters relating to the 164 
development stage of the project, the allogeneic or autologous nature of the product,  dosage 165 
per treatment, clinical application, planned process technologies,  proposed product price, 166 
expected market uptake, the cost of capital, tax rate, staff requirements, and assumptions 167 
about a range of costs. The tool makes these estimates based on default values that the user 168 
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may override with project-specific values. The project valuation is calculated using the risk-169 
adjusted Net Present Value (rNPV) valuation method, by discounting future cash flows by a 170 
discount rate that reflects the project’s riskiness and the firm’s cost of capital. rNPV is a 171 
profitability indicator that must be positive to justify the investment made, and the higher this 172 
value is the better project outcome. For rNPV of a cell therapy project estimation, the tool 173 
also utilises a database with information on clinical trial development times and failure rates 174 
of all 592 commercial cell therapy projects that entered development from 1981 until the end 175 
of 2011. Based on information about development times for each subsequent development 176 
stage, and failure rates of similar projects to the one for which parameters are provided, the 177 
tool estimates the expected duration of subsequent development stages and the rate that is 178 
used to discount future cash flows and to calculate the project’s rNPV. The parameters that 179 
are used to identify similar projects are the product type (i.e. allogeneic versus autologous), 180 
and the stage of development of the project (i.e. pre-clinical, stage 1, 2, or 3). Accordingly, 181 
the discount rate used for the rNPV is a project-specific discount rate that, apart from being 182 
based on the firm’s cost of capital that is provided by the user, is based on the riskiness and 183 
the expected development times for a particular project.  Payback time was calculated as the 184 
initial investment before market entry divided by the average annual cash flows after market 185 
entry. 186 
Case Study Setup 187 
A case study was set up that addressed a key challenge faced by cell therapy manufacturers 188 
related to understanding the financial implications of continuing to use standard planar 189 
processes throughout all the clinical phases of development through to market, versus 190 
switching to more cost-effective and scalable microcarrier-based single-use bioreactors either 191 
at early or late phases of development or post-approval. 192 
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The case study focused on an allogeneic mesenchymal stromal cell (MSC) candidate with a 193 
single-dose administration of 2 x 10
8
 cells. The manufacturing scales were determined based 194 
on the demand for clinical trial patient numbers considered representative for allogeneic cell 195 
therapies and overage (e.g. to cover stability tests). Commercial scale demand scenarios of 196 
10,000, 50,000 and 100,000 patients were explored. Table 2 summarises the different 197 
manufacturing process change scenarios of the case studies and specifies the different points 198 
of switching from planar to microcarrier-based technologies for these scenarios. For phase 3, 199 
although it is possible to use a smaller single-use bioreactor than 100L, it was assumed that it 200 
was best to keep this scale the same as commercial scale. Similarly, although it is possible to 201 
use a smaller bioreactor than 50L at phase 2, it was necessary to use this size of the bioreactor 202 
to allow for appropriate scale-up of mesenchymal stem cells to 100L at phase 3. It was 203 
assumed that volume reduction was performed by tangential flow filtration and that the 204 
product was cryopreserved.   205 
The microcarrier scenarios explored were based on the adoption of non-porous xeno-free 206 
microcarriers with a surface area of 2930 cm
2
/g and a microcarrier concentration of 6.3 g/L in 207 
the culture. Synthetic-coated microcarriers were assumed since expansion folds that were 208 
comparable to those coated with collagen have been recently reported for mesenchymal stem 209 
cells [18]. In addition, serum-free media was assumed. Together, these represented a more 210 
favourable regulatory compliant approach.  211 
The method of estimation of process development and technology transfer costs, in this case 212 
study, is demonstrated in Appendix 1, and that for the cost of stability studies is illustrated in 213 
Appendix 2. For process development and technology transfer activities, it was assumed that 214 
for every unit of FTE year workload, the cost incurred to the company was $250,000. Thus, 215 
the cost in each phase was equal to the product of the total duration of activity in the phase in 216 
years, the cost per FTE and the total number of FTE’s. Table 5 shows cost estimates for 217 
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product stability testing, comparability and bioequivalence tests, PPQ batches, 218 
manufacturing, and clinical trials. For stability studies, stability tests were performed at 0, 3, 219 
6, 9, 12, 18, 24, 36 and 48 months, or for fewer time points depending on which assays were 220 
considered [11]. It was assumed that stability studies start at phase 1, and are repeated if there 221 
is a process change. It was also assumed that these studies would also be performed on PPQ 222 
batches (3 different lots from 3 different donors). Stability tests were carried out on overage 223 
of material produced for clinical trials and PPQ batches. For planar processes, this overage at 224 
phase 1, 2 and 3 was 8, 3, and 80 x10
7 
cells/lot respectively, as the amount of cells produced 225 
by the optimal technology was greater than the amount of required for clinical studies. For 226 
microcarrier-based single-use bioreactors (MC-SUB) processes, the overage at phase 1, 2 and 227 
3 was 1, 9 and 20 x 10
9
 cells/lot respectively. In general, the more cells required for trials, the 228 
greater the overage produced by optimal technologies. For PPQ batches completed before US 229 
Food and Drug Administration (FDA) approval and comparability batches performed in the 230 
event of a process change, it was assumed that this was done using three separate lots at the 231 
same scale as the forthcoming market scale upon initial market entry. For comparability tests, 232 
additional assay tests were accounted for that each cost around $0.25 million, and in vivo 233 
studies in 10 animals for an initial $0.4 million, assuming a good surrogate model was 234 
available. 235 
For manufacturing costs, it was assumed that there were three manufacturing lots for Phase 1, 236 
three lots for Phase 2, 18 lots for Phase 3 and 100 lots for market production. 237 
For clinical trials, the number of patients in phase 1, 2 and 3 trials were set as 15, 32 and 240, 238 
respectively.  It was assumed that a process change necessitates a bridging study with an 239 
additional 15 patients. Clinical trial costs per patient were harder to determine due to different 240 
trends reported in the literature; examples for biopharmaceuticals in literature tended to 241 
suggest clinical costs per patient increase with the phase of development [19] whereas other 242 
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sources suggest clinical costs per patient often decrease with phase [20]. For our case study, 243 
we used the example in [21] where costs per patient for oncology drugs increases from phase 244 
1 to phase 2 from $45,200 to $69,700 and then to $74,800 at phase 3 (excluding overheads, 245 
Appendix 3). Overhead costs related to clinical trials were included in this analysis 246 
(Appendix 3). A decreasing overhead cost as a percentage of the total clinical trials cost was 247 
assumed at 15%, 9%, 2% of the total clinical trial cost in phase 1, 2, and 3 respectively.  248 
Regarding the post-approval commercialisation of the product, the cell therapy product was 249 
assumed to be marketed for seven years at a price of $10,000 per treatment to a market of 250 
10,000, 50,000, or 100,000 patients. A market penetration of 40% was assumed in the first 251 
year after launch, 80% in the second year after launch, and 100% after the third year. Sales 252 
and marketing costs are assumed to be 30% of costs of goods sold, in line with similar costs 253 
that are typical for biopharmaceuticals [22]. A corporate tax rate of 24% was assumed. 254 
Capital investment was accounted for in the cash flow, and it was assumed that a 255 
manufacturing facility would be built for market production, with construction commencing 256 
three years before market launch. 257 
Finally, cash flows were discounted using an assumed cost of capital rate of 10%, as well as 258 
the risk of failure of the project. These risks were quantified based on information from the 259 
cell therapy valuation tool on median failure rates for allogeneic cell therapy projects; For a 260 
generic allogeneic cell therapy product, the chance the project progresses to phase 2, 3 and 261 
FDA approval stage was estimated to be 87%, 55%, and 36% respectively. 262 
 263 
 264 
 265 
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Monte Carlo analysis 266 
Monte Carlo analysis was used to capture the impact of uncertainties on the key metrics. The 267 
Monte Carlo analysis was conducted using Palisade @Risk
®
 6 software (Palisade 268 
Corporation, NY, USA). A triangular distribution was assumed for all variable parameters. 269 
Factors to vary were determined from sensitivity analyses. For total expected out-of-pocket 270 
costs, variables included process development effort for microcarrier-based single-use 271 
bioreactors (including both process development and technology transfer costs), the total cost 272 
of PPQ batches, the cost of comparability and bioequivalence, and clinical trial costs, each 273 
varied by ±50%. The clinical phase transition probabilities were assigned triangular 274 
distributions with minimum, most likely and maximum values based on our findings. These 275 
included a triangular distribution Tr (77%, 87%, 93%) for the probability of entering phase 2, 276 
Tr (45%, 55%, 92%) for entering phase 3, and Tr (30%, 36%, 65%)  for entering FDA 277 
approval stage. For rNPV, triangular probability distributions were assigned to the 278 
commercial COG/dose at ± 30%, market size at ± 30%, selling price with Tr (8,000, 10,000, 279 
25,000), corporate tax rate with Tr (17%, 24%, 40%), and discount value with Tr (8%, 10%, 280 
25%). For the post-approval switch, due to possible regulatory hurdles associated with the 281 
late switch, the probability of entering FDA approval stage and market was altered by ± 30%, 282 
i.e. Tr (25%, 36%, 47%). Two-sample T-tests were performed on the resulting data to 283 
establish whether there was a statistically significant difference between the results for 284 
processes involving microcarrier-based single-use bioreactors and the base case (planar 285 
process). This analysis was done using OriginPro 9.1.0, Origin Lab Corporation, 286 
Northampton, MA, USA. 287 
 288 
 289 
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Results and Discussion 290 
The process change evaluation framework was used to assess the impact of technology 291 
switches from planar to microcarrier-based single-use bioreactors at different stages in the 292 
cell therapy product development pathway (i.e. phase 1, 2, 3 or post-FDA approval). The key 293 
economic outputs related to out-of-pocket costs during drug development and net present 294 
value or project valuation were initially evaluated deterministically. Scenario analyses are 295 
presented to highlight the combinations of business factors that influence the ranking of the 296 
solutions. The impact of the risk of making process technology changes and uncertainties in 297 
their performance was also analysed. 298 
 299 
Drug development cost perspective on process change evaluation 300 
The impact of market size and expansion technology choice on the commercial cost of goods 301 
per dose (COG/dose) was analysed. Figure 2a compares the commercial COG/dose for a 302 
market size of 10,000, 50,000 or 100,000 patients, where cell expansion is either performed 303 
by planar 40-layer cell factories to produce the allogeneic cell therapy product or using 100L 304 
microcarrier-based single-use bioreactor(s) for cell expansion. This figure illustrates that the 305 
commercial COG/dose for MC-SUB processes are significantly reduced compare to that for 306 
planar processes, 40% cheaper for a market size or 10,000, or 70% cheaper for a market size 307 
of 50,000 or 100,000 patients.  308 
The effect of phase of development and point at which the technology switch is made, on 309 
development costs, PPQ batches, manufacturing costs and clinical trial costs were also 310 
assessed. Figure 2b shows the expected out-of-pocket costs across each phase of product 311 
development with activity breakdowns. This parameter is calculated by summing the total 312 
cost in each phase multiplied by the probability of transition into each phase. This figure 313 
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shows that Phase 3 and FDA approval stages are the most expensive steps in the product 314 
development cycle. This can be attributed to the high clinical trial costs at Phase 3, and the 315 
expensive PPQ batches at the FDA approval stage. Figure 2c shows that starting in 316 
microcarrier-based single-use bioreactors (MC-SUBs) is best from a development 317 
perspective. The reason for this is that PPQ batches are significantly lower than sticking with 318 
planar processes (PL) or switching to MC-SUBs post-approval (MC-PA) where the product is 319 
commercially produced in planar vessels in the PL scenario and for the first year in the 320 
market in MC-PA scenario. Also, since the product is already produced in microcarrier-based 321 
single-use bioreactors from Phase 1 in MC-P1, the development costs should be lower than if 322 
the switch from planar vessels is made during subsequent stages (a change to MC-SUBs at 323 
phase 3 (MC-P3) and a change to MC-SUBs at phase 2 (MC-P2)). 324 
From Figure 2c, it can be seen that non-clinical costs for cell therapy were found to be around 325 
60% of the total drug development costs. This proportion differs to biologics where non-326 
clinical costs are typically around 20-30% of the total drug development costs [23,24]. This 327 
difference is mainly due to the much lower total clinical trial costs for cell therapy versus 328 
biologics, due to fewer patient numbers required in phase 1 to 3 trials. (The data in Figure 2c 329 
is shown in Appendix 4). 330 
Lifecycle profitability perspective on process change evaluation  331 
The economic output of lifecycle profitability was assessed with market size and point at 332 
which the technology switch is made. Profitability was assessed with risk-adjusted net 333 
present value, rNPV, and a high and positive rNPV value was indicative of an enhanced 334 
project outcome. Figure 2d shows that from a lifecycle profitability perspective using the 335 
rNPV metric, switching to microcarrier-based single-use bioreactors (MC-SUBs) post-336 
approval should be optimal. This figure shows that the rNPV for MC-PA was four-fold 337 
  15 
greater than the standard planar process at a market size of 10,000 patients, 1.5 fold greater at 338 
a market size of 50,000 patients, and 1.4 fold greater at a market size of 100,000 patients. The 339 
higher rNPV can be attributed to the fact that there are no delays associated with market entry 340 
since the costs for new expansion technology development are incurred while sales start with 341 
the product made using planar vessels in the first year of market penetration. (It was assumed 342 
that 40% of the target market is penetrated in the first year of launch). The case in which the 343 
product is manufactured using planar vessels throughout its lifecycle is the least favourable 344 
from an rNPV perspective, indicating a switch to the more scalable MC-SUBs at any stage in 345 
the development lifecycle is better than not making a switch. The difference in rNPV 346 
between the case where the process starts in MC-SUBs (MC-P1) and the case where 347 
expansion is always planar (PL) is less marked than expected; a three-fold difference in rNPV 348 
at a market size of 10,000 patients, and a 1.3 fold rNPV difference at a market size of 50,000 349 
and 100,000 patients. This finding was due to the assumed total number of years on the 350 
market of 7 years excluding delays. At two years on the market, with a market size of 50,000 351 
patients, excluding delays, the rNPV of MC-P1, (using MC-SUBs throughout, starting in 352 
phase 1), is double that of PL (staying with planar technologies throughout). At a market size 353 
of 10,000 patients, payback time is lowest for PL (11.5 years) and MC-P1 (11.6 years). At the 354 
higher market size of 50,000 patients, payback time is lowest for MC-PA, (10.5 years) and 355 
PL (10.8 years). At the highest market size of 100,000 patients, however, payback time is 356 
shortest for MC-PA (10.4 years), MC-P1 (10.8 years) and PL (10.8 years). For all market 357 
sizes, the intermediate switches to MC-SUBs at phase 2 or 3 have the longest payback time.  358 
Sensitivity analysis 359 
The sensitivity of total expected-out-of-pocket costs to various parameters was analysed. 360 
Figure 3 illustrates the sensitivity analyses results for a target market size of 50,000 patients 361 
(base case). The graphs in Figures 3 a, b, and c show that total expected-out-of-pocket cost 362 
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(TEOPC) is most sensitive to PPQ batches, and clinical trial costs for all cases. Also, TEOPC 363 
is also sensitive to comparability costs if the process change is made later in the development 364 
phase i.e. at phase 3 or post-approval. Figures 3 d and e show that rNPV is, however, most 365 
sensitive to selling price, market size, and discount rate, with similar profiles for all cases 366 
involving microcarrier-based single-use bioreactors. In addition to these factors, for the 367 
planar process, rNPV is also quite sensitive to COG/dose and fixed capital investment due to 368 
the high associated manufacturing cost related to using this technology at commercial scale 369 
of 50,000 patients, (Figure 3d). 370 
 371 
Scenario analyses: effect on the ranking of cases with respect to cost and rNPV 372 
This section describes the results of the different scenario analyses so as to gain greater 373 
insight into the critical levels of key technical, clinical and commercial features of cell 374 
therapy development that lead to a switch in the rankings of the process change cases. 375 
Impact of process development effort on expected out-of-pocket costs 376 
The impact of being able to reduce the extra process development effort required with 377 
microcarrier cultures on the ranking of cases was explored for different market sizes (Figures 378 
4a and b). Here process development effort includes process development, technology 379 
transfer, stability, comparability and clinical trials costs associated with microcarrier-based 380 
cell cultures. In reality, current process development efforts associated with MC-SUBs can be 381 
improved by using further advanced microcarriers that combine a high-surface area for high 382 
growth levels of mesenchymal stem cells, with ease of recovery to minimise losses after 383 
expansion and trypsinisation. Also, to improved microcarrier development, this could include 384 
enhanced protocols for cell recovery from the microcarriers from microcarrier suppliers. 385 
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Other factors that could reduce current development efforts associated with this are the 386 
incorporation of the design of experiments statistical tool and the use of ultra-scale down 387 
techniques [25-27] such as small-scale bioreactors and automation, for rapid screening and 388 
optimisation.  389 
Figure 4 illustrates that overall, switching post-approval remains more costly regarding total 390 
expected out-of-pocket costs irrespective of any decreases in process development effort and 391 
market size. However, for the cases of switching to MC-SUBs at Phases 1-3, reductions in 392 
process development effort relative to the base case assumption can have an impact on their 393 
ranking compared to the standard planar approach. More specifically, in this case study, for 394 
these pre-approval switches to MC-SUBs to have equally competitive or lower out-of-pocket 395 
costs to the planar process, the process development effort needs to drop by 25-50% for a 396 
market size of 10,000 patients (Figure 4a) and 5-25% for 50,000 patients (Figure 4b). In 397 
contrast, for a larger market size of 100,000 patients, the early pre-approval switch cases (MC 398 
P1, MC P2) can tolerate up to a 25% increase in process development effort above the base 399 
case assumption and still be competitive with the planar case, (data not shown). 400 
Impact of COG/dose on rNPV 401 
The impact of commercial COG/dose for planar and microcarrier-based cell cultures and 402 
market size on the ranking of cases with regards to profitability expressed as rNPV was 403 
performed. Figure 4c shows the results for a market size of 10,000 patients. At this low 404 
market size, switching post-approval or starting in MC-SUBs has the highest rNPV, and 405 
planar processes the lowest. A 50% increase in COG/dose for MC-SUBs makes starting in 406 
MC-SUBs or switching to MC-SUBs post-approval slightly less competitive than the planar 407 
process. If however, the market size is increased to 50,000 (Figure 4d), switching to MC-408 
SUBs post-approval, has the highest rNPV always and sticking to planar processes, the 409 
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lowest. A change in commercial COG/dose has no effect on the ranking of the cases. At a 410 
market size of 100,000 patients, the trends for impact on COG/dose on rNPV were similar to 411 
50,000 patients, (data not shown).  412 
COG/dose and market size 413 
Figures 5 a-c show two-way sensitivity analyses to show the effect of commercial COG/dose 414 
and market size on the % change in rNPV relative to planar processes for a late to early 415 
switch, i.e. MC-PA (Figure 5a), MC-P3 (Figure 5b) and MC-P1 (Figure 5c). Light grey 416 
regions on these charts are representative of areas where the rNPV for MC-SUB processes are 417 
greater than that for traditional planar processes and are thus preferable approaches. These 418 
figures show that switching to MC-SUBs post-approval, or starting in MC-SUBs offers the 419 
greatest window of flexibility to account for variation in market size and commercial 420 
COG/dose for MC-SUBs. For MC-PA, the cost of switching occurs during the first year of 421 
market penetration, (with the planar process in Year 1 of launch). MC-P1 offers lower PPQ 422 
costs. When the switch is made at phase 3 (Figure 5b) or 2 (data not shown), the operating 423 
window for switching to MC-SUBs is smaller due to the greater cost of development if the 424 
change occurs at this late stage. This indicates that late phase switches are more sensitive to 425 
the market size and the relative difference in the COG/dose between MC-SUBs and planar 426 
systems. For example, if the MC-SUBs COG/dose turns out to be over 50% higher than 427 
originally anticipated, then the switch to MC-SUBs becomes unfavourable if the market size 428 
is also below ~40,000 patients in the late stage MC-P3 scenario (Figure 5b). In contrast, the 429 
critical market size drops to ~20,000 patients in the MC-PA and MC-P1 scenarios at 50% 430 
higher COG values for MC-SUBs (Figure 5a and c). Hence, the attractiveness of the switch, 431 
as measured by rNPV, is largely unaffected by COG/dose and market size changes for the 432 
post-approval and early phase scenarios.  433 
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Market size and selling price 434 
Figures 5 d-f show the effect of variation in market size and selling price on the percentage 435 
change in rNPV relative to that for planar processes, with the light grey regions representing 436 
areas where rNPV is greater using MC-SUB processes than the standard planar process. This 437 
type of analysis is useful in demonstrating that if the selling price is increased beyond the 438 
base case of $10,000 per dose, a post-approval switch will still have a greater rNPV than that 439 
for planar processes. For example, at a higher selling price of $25,000 per dose, the model 440 
results predict that a post-approval switch would have a favourable rNPV relative to planar 441 
processes, while starting in MC-SUBs would give an equally competitive rNPV to planar 442 
processes, but intermediate switches at phase 3 or phase 2 (data not shown) would result in a 443 
lower rNPV in comparison to planar processes. 444 
COG/dose and drug development effort 445 
Figures 2d and 5 have shown that MC-PA, followed by MC-P1 are the optimal cases 446 
from a lifecycle profitability (rNPV) perspective. Figure 6 assesses whether MC-PA and MC-447 
P1 remain optimal solutions in terms of the highest rNPV when total process development for 448 
MC-SUBs, market size and commercial COG/dose for MC-SUBs are varied. Figures 6a-c 449 
show the effect of a change in the process development effort needed for switching to MC-450 
SUBs and the commercial COG/dose for MC-SUBs on the window where switching to MC-451 
SUBs wins over sticking to planar systems. The window where rNPVMC > rNPVPL is 452 
indicated by the light grey region of these plots  for scenarios where the switch is made 453 
progressively earlier and for a market size of 10,000 patients (Figures 6a-c) or 50,000 patients 454 
(Figures 6d-f). Here total process development effort for MC-SUBs includes process 455 
development, technology transfer, stability, comparability and extra clinical trials associated 456 
with making a process change. For commercial production, the cost of goods for 457 
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microcarrier-based single-use bioreactors (COGMC) was lower than the cost of goods for 458 
planar vessels (COGPL).  459 
Figure 6  illustrates that if the COG difference between the MC and PL systems is 460 
greater than anticipated (e.g. % change in COGMC/dose = -20%) then the MC-PA and MC-P1 461 
options still win over sticking to planar systems irrespective of the cost of development and 462 
market size. However, if the microcarrier options prove more costly to operate than assumed 463 
(e.g. % change in COGMC /dose = + 20%) then the decision to switch to microcarriers in 464 
bioreactors becomes sensitive to the cost of development at the lower market size of 10,000 465 
patients.. If this COG increase is accompanied by increases in process development cost in 466 
the order of 20%, then the planar options win in terms of overall profitability for the MC-PA 467 
and MC-P1 scenarios (Figures 6a and c). .In contrast, switching at phase 3 (MC-P3) is only 468 
favourable if the process development effort for MC-SUBs can be reduced by ~40% for cases 469 
where the COGMC/dose is higher than expected by 20% (Figure 6b), 470 
Figures 6d-f show that for a market size of 50,000 patients, switching to MC-SUBs is 471 
better than planar processes from an rNPV perspective irrespective of the timing of the 472 
change, the cost of development or the COG/dose, as indicated by the wide windows of 473 
operation.   474 
 475 
 476 
Robustness of each process change strategy 477 
The study was extended to characterize the variability in the total expected out-of-pocket 478 
costs and rNPV values caused by fluctuations in technical, clinical and commercial variables. 479 
The following discussion highlights the key findings from this analysis and assesses the 480 
robustness of the process change strategies.  481 
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Figure 7a shows frequency distribution plots generated from the Monte Carlo analysis, 482 
illustrating total expected out-of-pocket cost under uncertainty of the probability of entering 483 
the next phase of trials or FDA approval stage, including the costs of process development, 484 
technology transfer, clinical trials, comparability and bioequivalence, and PPQ batches. 485 
Options with the lowest mean costs and narrowest distributions, and hence less risk, are 486 
preferred. This figure indicates that the widest distribution in total expected out-of-pocket 487 
cost is for a post-approval switch, suggesting that this option has the highest likelihood of 488 
exceeding a particular cost budget. This distribution suggests that if a switch is to be made, an 489 
earlier switch to MC-SUBs would be less of a risk from a budget perspective.  Two-paired T-490 
tests (p < 0.05) established that the total expected out-of-pocket cost distributions for MC-491 
SUB processes were significantly lower (MC-P1, MC-P2) or higher (MC-P3, MC-PA) than 492 
the planar process. Hence, the ranking of best to worst process with respect to total expected 493 
out-of-pocket costs, under conditions of uncertainty and risk, are MC-P1, MC-P2, PL, MC-494 
P3, and MC-PA. This ranking was similar to deterministic values in Figure 2c where 495 
uncertainty was unaccounted. Figure 7b shows similar plots for rNPV under the uncertainty 496 
of market size, selling price, commercial COG/dose, tax rate and discount value, and the 497 
profiles and variation in rNPV are similar regardless of the case. For the post-approval switch 498 
(MC-PA), uncertainty in transition to market phase was introduced to account for potential 499 
regulatory hurdles introduced by the late switch. Two-paired T-Tests showed that the cases 500 
where the switch occurs post-approval or starting in MC-SUBs have significantly higher 501 
rNPVs (p < 0.05) than the planar process. However, there was no statistical difference 502 
between the planar process and switching to MC-SUBs at phase 2 or phase 3. The ranking of 503 
processes with respect to highest to lowest rNPV when and uncertainty is taken into account 504 
are switching to MC-SUBs post-approval and starting in MC-SUBs as equally optimal,  505 
followed by planar processes or switching at phase 2 or at phase 3. This is similar to 506 
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deterministic risk-adjusted rNPV values in Figure 2d where switching to MC-SUBs post-507 
approval was optimal, followed by starting in MC-SUBs. Although more development work 508 
with microcarriers is needed, starting in MC-SUBs may be more optimal than a later switch 509 
as there is a lower associated risk of the cells being biologically different concerning 510 
functionality in three-dimensional cultures, than in planar, two-dimensional cultures. 511 
This analysis was performed for a case study examining allogeneic mesenchymal stromal 512 
cells, and thus, we anticipate that different trends could be seen for autologous mesenchymal 513 
stromal cells (MSCs), and for other cell types such as pluripotent cells, which also include a 514 
differentiation step. Furthermore, this analysis assumed that 3D culture of MSCs was on 515 
microcarriers in single-use bioreactors. Studies are showing that MSCs grown as aggregates 516 
in suspension in bioreactors may give comparable or better growth conditions than planar 517 
systems [28, 29]. Future research would determine whether this would have an impact on the 518 
cost and profit implications examined in this case study, as well as on the ranking of the 519 
optimal time to switch to 3D culture. Overall this analysis can help to determine the effect of 520 
timely process changes on total development costs, rNPV, associated risk, and variation in 521 
critical factors. As more cell therapy products are commercially produced at larger scales 522 
using newer microcarrier-based single-use bioreactor technologies, successes, failures and a 523 
more developed regulation pathway will help to determine the success of key manufacturing 524 
processes and business models. 525 
Conclusions 526 
For the commercial production of allogeneic mesenchymal stromal cells for some high dose 527 
indications such as graft-versus-host disease (GvHD) or cardiac disease, a switch in cell 528 
expansion technologies from traditional planar technologies, such as cell factories, to more 529 
scalable microcarrier-based single-use bioreactors, may be necessary. A process change 530 
framework was applied to a case study assessing a dose of 2 x 10
7
 cells per patient for a 531 
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market size of 10,000, 50,000 and 100,000 patients. In addition to manufacturing costs, costs 532 
of process development, technology transfer, clinical trials, and comparability were assessed. 533 
Implications of different manufacturing process technology strategies were analyzed for total 534 
expected out-of-pocket costs and the project’s profitability (rNPV). In our assessment and 535 
under the assumptions used in the framework, intermediate switches at phase 2 or phase 3 536 
were less favourable than either using microcarrier-based single-use bioreactors throughout, 537 
starting in phase 1, or making the switch post-approval. However, in our assessment, it was 538 
always better to switch than never to switch. If the scenario of starting in single-use 539 
bioreactors is compared to switching post-approval, a post-approval switch is more 540 
advantageous from a profitability perspective, and in the possible event that the selling price 541 
is significantly higher than assumed (£10,000 per treatment). Starting in microcarrier-based 542 
single-use bioreactors overall is more favourable due to the lower total expected-out of-543 
pocket costs, and the fact that that rNPV is not much less than a post-approval switch. 544 
Moreover, such a strategy allows for wider unexpected changes in process development 545 
effort for microcarrier-based single-use bioreactors, bridging study size, market size and 546 
commercial COG/dose. Overall, there should be less risk of a wide variation in total costs 547 
when the switch to microcarrier-based single-use bioreactors is made early at phase 1, rather 548 
than at the post-approval stage. This analysis can help to manage better the risks associated 549 
with process changes at different stages of the product’s development lifecycle. 550 
 551 
 552 
 553 
 554 
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 555 
 556 
 557 
Executive summary 558 
Production of commercial allogeneic mesenchymal stem cells 559 
 Allogeneic mesenchymal stem cells produced at commercial scale for some high dose 560 
indications may necessitate a process change from traditional planar cell expansion 561 
technologies to microcarrier-based single-use bioreactors. 562 
Decisional tool 563 
  A decisional tool comprising a process change evaluation framework, was developed 564 
for a case study assessing a dose of 2 x 10
7
 cells per patient for a market size of 565 
10,000, 50,000 and 100,000 patients.  566 
 Total expected out-of-pocket costs including manufacturing costs, and costs of 567 
process development, technology transfer, clinical trials, and comparability were 568 
included.  569 
 rNPV was also assessed to compare switching at phase 1, 2, 3 or post-approval.  570 
 571 
Conclusion 572 
 The results of this analysis are dependent on the assumptions used in the framework. 573 
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 Switching to microcarrier-based single-use bioreactors at the beginning of phase 2 or 574 
phase 3 are financially less favorable compared to switching at the beginning, phase I 575 
or after approval (if bioequivalence can be shown). 576 
 But, switching is always better than never switching.  577 
 A post-approval switch gives the highest rNPV, and is more robust to significant 578 
increases in selling price.  579 
 Starting in microcarrier-based single-use bioreactors overall is the best approach due 580 
to its lower total expected-out of-pocket cost, a high rNPV, and is less susceptible to 581 
changes in process development effort for microcarrier-based single-use bioreactors, 582 
bridging study size, market size and commercial COG/dose.  583 
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MC-P1:  MC-SUBs throughout (starting in phase 1) 599 
MC-P2: Change to MC-SUB at Phase 2 600 
MC-P3: Change to MC-SUB at Phase 3 601 
MC-SUB: microcarrier-based single-use bioreactor 602 
MSC: mesenchymal stromal cell 603 
PD: process development  604 
Ph: Phase of clinical trial 605 
PL: planar vessels 606 
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TEOPC: total expected-out-of-pocket cost 615 
Sterility USP: Sterility, United States Pharmacopeia 616 
Tr: triangular distribution (in Monte Carlo analysis) 617 
USP: Upstream processing 618 
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Table 1: Assumptions of activities that occur in a product’s development lifecycle, phases of the lifecycle in which these activities are performed, and the cost 
basis of calculations used in this case study to estimate the total cost of these activities. Ph: clinical trial phase; FTE: full-time equivalent workload; FDA app: 
Food and drug administration approval; PPQ: Process performance qualification; COG: cost of goods; CPP: critical process parameter; PLE: process limit 
evaluation. 
  
  
Process 
Development  
Comparability & 
Bioequivalence  
Technology 
Transfer 
Process 
performance 
qualification  
 
Product stability Clinical 
material 
production 
Clinical trials 
Assumptions of 
activities involved 
 
 
 
Cell 
characterisation, 
Assay 
development, 
Assay qualification, 
Process 
optimisation, 
Equipment 
validation 
In vitro (assay cost) and 
in vivo (animal model 
surrogate). If process 
change: additional but 
fewer lots at the same 
scale using the old 
process to demonstrate 
equivalence in clinic. 
Process is then locked.  
Identification of 
5-10 CPPs and 
performing PLE 
studies, 
Documentation, 
Training 
3 PPQ        
batches  
Stability tests & 
assays (use 
conformance 
batches as want 
shelf life to be as 
long as possible). 
Engineering 
runs, Clinical 
production 
Clinical trial 
costs, Extra 
clinical trial 
cost if 
process 
change 
When occurs 
Ph 1/2/3 (& FDA 
app if there is a 
post-approval 
change)  
At the stage of process 
change for 
comparability/bioequivale
nce & in vitro testing & at 
Ph 1 for in vivo testing 
Ph 1/2/3/FDA app FDA app 
Starts at Phase 1, 
repeated if there is 
a change and done 
again at FDA app 
stage (final process) 
Ph1/2/3 
Ph1/2/3 (& 
FDA app if 
there is a post-
approval 
change) 
Cost basis FTE 
Cost per dose for 
additional batches using 
the old process & 
assumed in vitro/in vivo 
cost 
FTE 
COG/dose (includes 
assay validation 
cost as QC cost) 
Assay cost 
(includes material 
cost, labour cost, 
Indirect cost) 
COG/dose 
Clinical trial 
cost per patient 
  
Table 2: Cell expansion technologies used in each case and phase for allogeneic mesenchymal 
stromal cell therapy manufacturing. Downstream processing steps are assumed to be tangential flow 
filtration followed by cryovial filling for cryopreservation in all cases. CF-10: 10 layer cell factories; CF-
40: 40-layer cell factories; MC-SUB: microcarrier-based single-use bioreactors. 
 
Phase 1 Phase 2 Phase 3 
Market size 
(number of 
patients, 
x1000) 
FDA approval & 
Market 
PL: Planar 
technologies 
throughout 
 
10 x CF-10 
 
 
20 x CF-10 
 
 
8 x CF-40 
 
 
10 48 x CF-40 
50 232 CF-40 
100 464 CF-40 
MC-PA: Change to MC-
SUB post-approval 
 
10 x CF-10 
 
 
20 x CF-10 
 
 
8 x CF-40 
 
 
10 1x 100L MC-SUB 
50 2x 100L MC-SUB 
100 4x 100L MC-SUB 
MC-P3: Change to MC-
SUB at Phase 3 
 
 
10 x CF-10 
 
 
20 x CF-10 
 
 
1x 100L 
MC-SUB 
 
 
10 1x 100L MC-SUB 
50 2x 100L MC-SUB 
100 4x 100L MC-SUB 
MC-P2: Change to MC-
SUB at Phase 2 
 
 
10 x CF-10 
 
 
1x 50L 
MC-SUB 
 
 
1x 100L 
MC-SUB 
 
 
10 1x 100L MC-SUB 
50 2x 100L MC- SUB 
100 4x 100L MC-SUB 
MC-P1: MC-SUBs 
throughout  (starting in 
phase 1) 
1x 10L 
MC-SUB 
 
 
1x 50L 
MC-SUB 
 
 
1x 100L 
MC-SUB 
 
 
10 1x 100L MC-SUB 
50 2x 100L MC-SUB 
100 4x 100L MC-SUB 
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Table 3: Estimated costs in $ millions of product development, technology transfer, comparability and 
bioequivalence tests, process performance qualification (PPQ) batches, product stability testing, 
manufacturing, and clinical trials. Cost estimations were as in Table 1. Product development and 
technology transfer costs were estimated on a fixed time equivalent (FTE) basis, and example 
calculations are in Appendix 4. Stability costs were based on assay costs shown in Appendix 1. Data 
is shown for market sizes of 10,000, 50,000 or 100,000 patients. Any changes due to market increase 
to 50,000 are shown in round brackets, and any changes due to a market increase to 100,000 are 
shown in square brackets, if applicable. PL: planar throughout; MC-PA: Change to MC-SUB post-
approval; MC-P1: using MC-SUBs throughout, starting at phase 1; MC-P2: Change to MC-SUB at 
Phase 2; MC-P3: Change to MC-SUB at Phase 3; MC-SUB: microcarrier-based single-use bioreactor.  
    Phase 1 Phase 2 Phase 3 
FDA 
approval/Market 
Process 
Development  
PL 0.5 0.5 1.5   
MC-PA 0.5 0.5 1.5 5 
MC-P3 0.5 0.5 3   
MC-P2 0.5 3 3   
MC-P1 1.25 3 3   
Technology 
Transfer  
PL 0.5 0.5 1.5 2 
MC-PA 0.5 0.5 1.5 5 
MC-P3 0.5 0.5 1.5 5 
MC-P2 0.5 1.5 1.5 5 
MC-P1 0.75 1.5 1.5 5 
Comparability & 
bioequivalence  
PL  0.4       
MC-PA   0.4     9.71 (13.55) [26.23] 
MC-P3   0.4   
9.71 (13.55) 
[26.05] 
  
MC-P2   0.4 2.07     
MC-P1   0.4       
PPQ batches 
PL       12.8 (37.7) [73.1] 
MC-PA       15.9 (32.2) [62.5] 
MC-P3       9.5 (13.3) [26.0] 
MC-P2       9.5 (13.3) [26.0] 
MC-P1       9.5 (13.3) [26.0] 
Product stability  
PL 0.05 0.04 0 0.27 
MC-PA 0.05 0.04 0 0.53 
MC-P3 0.05 0.04 0.07 0.27 
MC-P2 0.05 0.1 0 0.26 
MC-P1 0.05 0.04 0 0.27 
MC-PA 1.15 1.23 4.55   
MC-P3 1.15 1.23 5.65   
MC-P2 1.15 1.82 5.65   
MC-P1  1.22 1.82 5.65   
Clinical trials  
PL 0.78 2.44 18.23   
MC-PA 0.78 2.44 18.23 1.22 
MC-P3 0.78 2.44 19.45   
MC-P2 0.78 3.58 18.23   
MC-P1 0.78 2.44 18.23   
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Figure 1: Process change model structure. Tech transfer: Technology transfer; PPQ: Process performance qualification. 
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Figure 2:  Assuming a dose of 200 million mesenchymal stromal cells, a) commercial cost of goods 
per dose (COG/dose) for an assumed market of 10,000, 50,000 and 100,000 patients, for a 
manufacturing process where cell expansion is performed by planar 40-layer cell factories, versus cell 
expansion in 100L microcarrier-based single-use bioreactors. b) For a market size of 50,000 patients, 
expected out-of pocket costs across phase and c) total expected out-of-pocket costs with activity 
breakdowns for planar process (PL), change to microcarrier-based SUB process post-approval (MC 
PA), change to MC-SUBs at phase 3 (MC P3), change to MC-SUBs at phase 2 (MC P2), or using 
MC-SUBs throughout, starting in phase 1 (MC P1). d) Risk adjusted net present value for these 
cases. Payback time in years is shown above the bars. 
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Figure 3: For a target market size of 50,000 patients (base case), Sensitivity analyses with respect to 
total expected-out-of-pocket costs to reach approval for a) planar technologies throughout, PL, b) 
change to microcarrier-based SUB process post-approval, MC-PA, or c) using microcarrier-based 
SUBs throughout, starting in phase 1, MC-P1. The sensitivity analysis plot for a change to MC-SUBs 
at phase 3 was similar to a change to MC-SUBs post-approval (data not shown). The sensitivity 
analysis plot for a change to MC-SUBs at phase 2 was similar to using MC-SUBs throughout, starting 
in phase 1 (data not shown).  Sensitivity analyses with respect to risk adjusted rNPV for d) planar 
technologies throughout, PL, e) change to microcarrier-based SUB process post-approval, MC-PA. A 
change to microcarrier-based SUBs at phase 3, phase 2, or Phase 1 had similar profiles to the post-
approval change (data not shown). PPQ: process performance qualification; COG/dose: cost of goods 
per dose; R&D: research and development. 
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Figure 4: The impact of a change in process development effort needed for microcarrier-based cell 
cultures on the ranking of cases with respect to total expected out-of-pocket costs for a market size of 
a) 10,000 and b) 50,000 patients. Here total process development effort includes process 
development, technology transfer, stability, comparability and extra clinical trials associated with 
making a process change. The impact of commercial COG/dose for microcarrier-based cell cultures 
on the ranking of cases with respect to total rNPV for a market size of c) 10,000 and d) 50,000 
patients. In this analysis it is assumed that the COG/dose for planar processes is fixed and that for 
MC-SUBs is varied. MC-SUB: microcarrier-based single-use bioreactor; COG/dose: cost of goods per 
dose; rNPV: risk-adjusted net present value; PL: planar technologies throughout; MC-PA: change to 
MC-SUBs post-approval; MC-P3: change to MC-SUBs at phase 3; MC-P2: change to MC-SUBs at 
phase 2; MC-P1: MC-SUBs throughout (starting in Phase 1). 
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Figure 5: Two-way analyses to show the effect of commercial COG/dose for MC-SUBs and market 
size on the % change in rNPV relative to planar processes for switching to microcarrier-based SUBs 
(a) post-approval, MC-PA, (b) at phase 3, MC-P3 (similar to phase 2, data not shown), and (c) at 
phase 1, MC-P1; Two-way analyses to show the effect of market size and selling price on the % 
change in rNPV relative to planar processes for switching to microcarrier-based SUBs (d) post-
approval, MC-PA, (e) at phase 3, MC-P3 (similar to  phase 2, data not shown), and (f) at phase 1, 
MC-P1. Dark grey regions indicates windows of operation that favours sticking with planar processes, 
and light grey regions labelled rNPVMC > rNPVPL represent windows of operation that favours 
switching to MC-SUBs, where rNPV is risk adjusted net present value, MC is microcarrier-based 
single-use bioreactors and PL are planar vessels. 
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Figure 6:  Two-way analyses to show the effect of % change in total process development effort for 
microcarrier-based cell cultures (MC-SUBs) and % change in COGMC on the percentage change in 
rNPV relative to planar processes for switching to MC-SUBs. Here total process development effort 
includes process development, technology transfer, stability, comparability and extra clinical trials 
associated with making a process change. Dark grey regions indicates windows of operation that 
favours sticking with planar processes, and light grey regions labelled rNPVMC > rNPVPL represent 
windows of operation that favours switching to MC-SUBs. Results shown for a market size of 10,000 
patients for switching to MC-SUBs a) post-approval, b) at phase 3 (similar to phase 2, data not 
shown) , c) at phase 1, and for a market size of 50,000 patients for switching to MC-SUBs d) post-
approval, e) at phase 3 (similar to phase 2, data not shown), f) at phase 1. (For a market size of 
100,000 patients, the results were very similar to 50,000 patients, data not shown). MC-PA: change to 
MC-SUBs post-approval; MC-P3: change to MC-SUBs at phase 3; MC-P2: change to MC-SUBs at 
phase 2; MC-P1: MC-SUBs throughout (starting in Phase 1).
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Figure 7: Frequency distribution plots for a market size of 50,000 patients, depicting (a) total expected out-of pocket cost under uncertainty of probability of 
entering the next phase of trials of Food and Drug administration (FDA) approval stage, process development costs (including process development and 
technology transfer), clinical trial costs, comparability and bioequivalence costs, and cost of process performance qualification (PPQ) batches. There was a 
statistically significant difference (p < 0.05) between all processes involving microcarrier-based single-use bioreactors (SUBs) and the planar process with 
(Two-paired T-test, Origin), as indicated by the asterisks above the graph. The mean ± SD for the planar process (PL), changing to microcarrier SUB process 
post-approval (MC PA), change to microcarrier-SUB process at phase 3 (MC P3), change to microcarrier-SUB process at phase 2 (MC P2), and starting in  
microcarrier-SUB process at phase 1 (MC P1), were 41.4 ± 6.0, 49.4 ± 7.8, 43.2 ± 6.1, 40.0 ± 5.0, and 38.2 ± 5.0 respectively; (b) Risk-adjusted net present 
value (rNPV) under uncertainty of market size, selling price, commercial cost of goods per dose (COG/dose), tax rate and discount value, and probability of 
transition to the market for the post-approval switch due in order to account for unexpected potential regulatory challenges. There was a statistically 
significant difference (p < 0.05) between the processes where the switch to microcarrier-based SUBs were made post-approval or at phase 1 and the planar 
process (Two-paired T-test, OriginPro 9.1.0), as indicated by the asterisks above the graph. The mean ± SD for the PL, MC PA, MC P3, MC P2, MC P1 were 
17.9 ± 11.1, 23.4 ± 12.8, 17.7 ± 9.80, 17.8 ± 9.9, and 20.1 ± 11.0 respectively. PL: planar throughout; MC-PA: Change to MC-SUB post-approval; MC-P1: 
using MC-SUBs throughout, starting at phase 1; MC-P2: Change to MC-SUB at Phase 2; MC-P3: Change to MC-SUB at Phase 3
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Appendix 1: Example calculations to estimate product development costs and technology transfer 
costs on an FTE basis. Assumed that on average for every unit of full-time equivalent (FTE) year 
workload, the cost incurred to the company is $250K. Cost in phase is the product of total duration of 
activity in the phase (in years), $250,000 and total FTE. QC: quality control; QA: quality assurance. 
    Phase 1 Phase 2 Phase 3 FDA approval 
Process 
Development ($ 
millions) 
Example 
Calculation 
for PL  
Total FTE = 1 
project manager + 3 
process scientists + 
1 QC/QA specialist 
= 5 
Total FTE 
= 1 project 
manager + 
3 process 
scientists + 
1 QC/QA 
specialist = 
5 
Total FTE = 1 
project manager + 
6 process 
scientists + 5 
QC/QA specialist 
= 12 
  
Duration = 0.4 yrs 
Duration = 
0.4 yrs 
Duration = 0.5 yrs 
Cost = $250,000 x 
5 x 0.4 = $0.5 
million  
Cost = 
$250,000 x 
5 x 0.4 = 
$0.5 million 
Cost = $250,000 x 
12 x 0.5 = $1.5 
million 
Technology 
Transfer ($ 
millions) 
Example 
Calculation 
for PL  
Total FTE = 1 
project manager + 4 
Technology transfer 
specialists + 1 
Regulatory support 
specialist = 6 
Total FTE 
= 1 project 
manager + 
5 
Technology 
transfer 
specialists 
+ 3 
Regulatory 
support 
specialist = 
9 
Total FTE = 1 
project manager + 
6 Technology 
transfer 
specialists + 2 
Regulatory 
support specialist 
= 9 
Total FTE = 1 project 
manager + 6 
Technology transfer 
specialists + 4 
Regulatory support 
specialist = 11 
Duration = 0.3 yrs 
Duration = 
0.2 yrs 
Duration = 0.65 
yrs 
Duration = 0.7 yrs 
Cost = $250,000 x 
5 x 0,.4 = $0.5 
million  
Cost = 
$250,000 x 
5 x 0,.4 = 
$0.5 million 
Cost = $250,000 x 
5 x 0,.4 = $1.5 
million 
Cost = $250,000 x 5 x 
0,.4 = $0.5 million 
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Appendix 2: Estimation of assays required and stability test costs in different phases of trials. The 
number of timepoints in different phases of trials shown below is for the case where  there is no 
process change, and these change accordingly if there is a change, considering that the duration of 
phase 1, 2, and 3 trials are considered to be 1.5, 2.5 and 3 years respectively. ELISA: enzyme-linked 
immunosorbent assay; Sterility USP: Sterility, United States Pharmacopeia 
Test Equipment Nr of stability timepoints   
  Phase 
1 
Phase 
2 
Phase 
3 
 Cost per assay Total cost 
of stability 
assays in 
Ph 1 
Cell count & Viability Nucleocounter 6 2 8 $ 0.4 K $ 2.4 K 
Sterility USP <71> thermal cycler 2 1 3 $ 1.9 K $ 3.8 K 
Mycoplasma <63> luminometer 2 1 3 $ 1.5 K $ 0.7 K 
Flow Markers flow cytometer 6 2 8 $ 1.7 K $ 10 K 
ELISA for Endotoxin 
analysis 
plate reader 2 1 3 $ 3.0 K $ 6.0 K 
ELISA for analysis of 
cytokines 
plate reader 6 1 3 $ 3.3 K $ 9.0 K 
ELISA for cell-based 
assay 
Plate reader 2 2 8 $5.0K $10.0K 
       Total $ 51 K 
     Total for 3 lots $154K 
 
Appendix 3: Summary of clinical trial costs per patient, cells/phase, number of assumed lots/year, 
and scale for planar and microcarrier-based single-use bioreactors, for a hypothetical dose of 200 
million mesenchymal stromal cells per patient. It was assumed that stability studies were performed 
using overage produced for clinical trials. Material for in vitro testing in comparability and 
bioequivalence studies was assumed to be produced in separate batches at the scale at which the 
expansion technology switch was made. MC-SUB: microcarrier-based single-use bioreactors; CF-10: 
10-layer cell factory; CF-40: 40-layer cell factory 
  Phase 1 Phase 2 Phase 3 FDA approval Market 
Numbers of patients 15 32 240 N/A 
10,000 to 
100,000 
Clinical trial cost per patient (excluding 
overheads) 
45200 69700 74800 N/A N/A 
Clinical trial cost per patient (including 
overheads) 
51867 76152 75954 N/A N/A 
Transition probability 100% 87% 55% 36% 
 
Cells/phase produced (Planar) 3.24 x 10
9
 
6.49 x 
10
9
 
6.23 x 
10
10
 
6.2 x 10
10 
to 6.0 
x 10
11
 
2 x 10
12 
to 
2E+13 
Cells/phase produced (MC-SUB) 6.35 x 10
9
 
3.18 x 
10
10
 
3.81 x 
10
11
 
6.4 x 10
10 
to 2.5 
x 10
11
 
2 x 1012 to 8.5 
x 10
12
 
Number of lots 3 3 18 3 100 
Scale if Planar 10 x CF-10 
20 x CF-
10 
8 x CF-40 48-464 CF-40 48-464 CF-40 
Scale if MC-SUB 1 X 10L 1x 50L 1 x 100L 1-4 x 100L 1-4 x 100L 
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Appendix 4: Assuming a dose of 200 million mesenchymal stromal cells and a market size of 50,000 
patients, total expected out-of-pocket costs in $ millions with activity breakdowns for planar process 
(PL), and the % change of total expected out of pocket costs for change to microcarrier-based SUB 
process post-approval (MC PA), change at phase 3 (MC P3), change at phase 2 (MC P2), or using 
MC-SUBs throughout, (starting in phase 1) (MC P1), relative to the planar base case. Note expected 
out-of-pockets costs take into account the probability of transition to each phase. 
 
  Development activities PPQ batches 
Manufacturing for clinical 
trials Clinical trials 
PL 4.8 13.6 4.7 12.9 
MC-PA +163% -15% +0% +3% 
MC-P3 +195% -64% +13% +5% 
MC-P2 +141% -65% +24% +8% 
MC-P1 +55% -184% +20% +0% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
